Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 1, 1986CirculationOpen Access

Clinical trials evaluating platelet-modifying drugs in patients with atherosclerotic cardiovascular disease and thrombosis.

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Do platelet-modifying drugs reduce thromboembolic and cardiovascular events in patients with atherosclerotic cardiovascular disease and thrombosis?

Population

Patients with atherosclerotic cardiovascular disease and thrombosis, including those with transient ischemic…

Design

Review

Authors

LHLaurence A. HarkerOpole University of Technology

Discussion

Loading...

Member takes

Overview

May inform early antiplatelet strategies in TIA and angina; leaves open optimal regimens amid modern therapies.

Key Points

  • The study aims to evaluate the effectiveness of various platelet-modifying medications in preventing thrombotic complications in patients with atherosclerotic cardiovascular disease.
  • Analyzed clinical trial data on aspirin, dipyridamole, and sulfinpyrazone in different patient populations affected by cardiovascular disease.
  • Examined the combination therapies for efficacy and compared individual drug effects.
  • Included studies on the prevention of myocardial infarction, stroke, and occlusion in specific cardiovascular conditions.
  • Aspirin reduces stroke and death in men with transient ischemic attacks (p<0.05).
  • Dipyridamole combined with oral anticoagulation decreases thromboembolic complications (exact effect size unspecified).
  • Sulfinpyrazone shows benefit in reducing occlusions, but effects on myocardial infarction prevention are debated.

Structured PICO

Do platelet-modifying drugs reduce thromboembolic and cardiovascular events in patients with atherosclerotic cardiovascular disease and thrombosis?

P
Population
Patients with atherosclerotic cardiovascular disease and thrombosis, including those with transient ischemic attacks, unstable angina, artificial heart valves, arteriovenous cannulae, and saphenous vein aortocoronary grafts
I
Intervention
Platelet-modifying drugs (aspirin, dipyridamole, sulfinpyrazone)
O
Outcome
Thromboembolic and cardiovascular events (stroke, death, myocardial infarction, graft occlusion)hard clinical

This review summarizes early clinical trial evidence supporting the use of antiplatelet agents like aspirin and dipyridamole for preventing thrombotic events in various cardiovascular conditions.

Cite This Study

Laurence A. Harker (1986) studied this question.

synapsesocial.com/papers/6a0ea44cb9cfc04f92479ed2https://doi.org/10.1161/01.cir.73.2.206

Topics

Women and heart diseaseAnticoagulation in AF
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Prevention of Thrombosis in Patients on Hemodialysis by Low-Dose Aspirin1979 · 251 citations
  2. 2Platelet-Inhibiting Drugs in the Prevention of Clinical Thrombotic Disease1975 · 111 citations
  3. 3Inhibition of Prostacyclin and Platelet Thromboxane A<sub>2</sub>after Low-Dose Aspirin1981 · 274 citations
  4. 4Persantine and aspirin in coronary heart disease. The Persantine-Aspirin Reinfarction Study Research Group.1980 · 470 citations
  5. 5Endogenous prostacyclin biosynthesis and platelet function during selective inhibition of thromboxane synthase in man.1983 · 138 citations